Analyst Ratings for Amylin Pharmaceuticals (AMLN)
AMLN Rating Summary
AMLN Price Target Summary
- Highest: $32.00 (Jefferies)
- Lowest: $8.00 (Rodman & Renshaw)
- Average: $18.50
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$18.50 (-40.3%)
Avg. $ Target:
$18.50 (-40.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/3/2012 | Morgan Stanley | Upgrade | Equalweight (Underweight) |
N/A (N/A) |
30.71 | 30.98 | 0.88% | Details |
| 7/2/2012 | BMO Capital | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
28.20 | 30.98 | 9.86% | Details |
| 5/31/2012 | Baird » Updated 7/2/2012 |
Downgrade | Neutral (N/A) |
31.00 (28.00) |
27.44 | 30.98 | 12.9% | Details |
| 3/29/2012 | MKM Partners | Upgrade | Neutral (N/A) |
22.00 (N/A) |
23.77 | 30.98 | 30.33% | Details |
| 3/28/2012 | Piper Jaffray | Downgrade | Neutral (N/A) |
21.00 (N/A) |
15.39 | 30.98 | 101.3% | Details |
| 3/26/2012 | Canaccord Genuity | New Coverage | Sell (N/A) |
12.00 (N/A) |
15.52 | 30.98 | 99.61% | Details |
| 2/16/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
22.00 (N/A) |
17.61 | 30.98 | 75.92% | Details |
| 1/30/2012 | Summer Street | Downgrade | Neutral (N/A) |
N/A (N/A) |
12.14 | 30.98 | 155.19% | Details |
| 1/5/2012 | Rodman & Renshaw | New Coverage | Market Underperform (N/A) |
8.00 (N/A) |
11.17 | 30.98 | 177.35% | Details |
| 12/7/2011 | Global Hunter Securities | New Coverage | Accumulate (N/A) |
14.00 (N/A) |
10.79 | 30.98 | 187.12% | Details |
| 7/8/2011 | BofA/Merrill Lynch | Upgrade | Neutral (N/A) |
N/A (N/A) |
13.71 | 30.98 | 125.97% | Details |
| 3/3/2011 | Hapoalim Securities | Downgrade | Sell (N/A) |
N/A (N/A) |
11.35 | 30.98 | 172.95% | Details |
| 2/8/2011 | Goldman Sachs » Updated 1/30/2012 |
New Coverage | Sell (N/A) |
11.00 (N/A) |
16.07 | 30.98 | 92.78% | Details |
| 10/27/2010 | Leerink Swann | Upgrade | Outperform (N/A) |
N/A (N/A) |
12.00 | 30.98 | 158.17% | Details |
| 10/20/2010 | Deutsche Bank | Downgrade | Hold (N/A) |
N/A (N/A) |
9.81 | 30.98 | 215.8% | Details |
